text
stringlengths 81
4.38k
|
|---|
<s>[INST] Provide the medical condition for trial id: NCT01879189 [/INST] Breast Cancer </s> |
<s>Trial Id: Detection of Circulating Tumor Cells in Breast Cancer Patients Using a Novel Microfluidic and Raman Spectrum Device Recruitment Status: Unknown status Trail description: Circulating tumor cells (CTCs) in peripheral blood originate from breast cancer (primary and metastatic lesions) shedding. Utilization of CTCs as novel and noninvasive tests for diagnosis confirmation, therapy selection, and cancer surveillance is a rapidly growing area of interest. In this project, the investigators will explore a novel detection technology of circulating tumor cells in breast cancer using novel Microfluidic and Raman Spectrum Device. The primary objective is to demonstrate that the CTC assay counts technology can distinguish between healthy subjects and malignant breast cancer subjects. The secondary objective is to demonstrate that the CTCs detection technology can evaluate the efficacy of chemotherapy and neoadjuvant chemotherapy, as well as dynamic treatment monitoring and prognosis evaluation. Inclusion Criteria: All subjects need to sign the informed consent form.
Age of at least 20 and at most 70 years.
Cancer group subjects with pathology report confirmed to be malignant.
Chemotherapy is necessary before or after surgery.
Control group need to have mammogram /ultrasound results category1-3.
Patients must be available for and compliant to treatment and follow-up. Exclusion Criteria: Not willing to sign the informed consent form.
Pregnant or lactating patients.
Prior or concomitant secondary malignancy.
Any other serious medical pathology, such as congestive heart failure.
Other condition which may affect the CTC results.
Males. </s> |
<s>[INST] Provide inclusion criteria for trial id: NCT04239105 [/INST] All subjects need to sign the informed consent form.
Age of at least 20 and at most 70 years.
Cancer group subjects with pathology report confirmed to be malignant.
Chemotherapy is necessary before or after surgery.
Control group need to have mammogram /ultrasound results category1-3.
Patients must be available for and compliant to treatment and follow-up. </s> |
<s>[INST] Provide exclusion criteria for trial id: NCT04239105 [/INST] Not willing to sign the informed consent form.
Pregnant or lactating patients.
Prior or concomitant secondary malignancy.
Any other serious medical pathology, such as congestive heart failure.
Other condition which may affect the CTC results.
Males. </s> |
<s>[INST] Provide description for trial id: NCT04239105 [/INST] Circulating tumor cells (CTCs) in peripheral blood originate from breast cancer (primary and metastatic lesions) shedding. Utilization of CTCs as novel and noninvasive tests for diagnosis confirmation, therapy selection, and cancer surveillance is a rapidly growing area of interest. In this project, the investigators will explore a novel detection technology of circulating tumor cells in breast cancer using novel Microfluidic and Raman Spectrum Device. The primary objective is to demonstrate that the CTC assay counts technology can distinguish between healthy subjects and malignant breast cancer subjects. The secondary objective is to demonstrate that the CTCs detection technology can evaluate the efficacy of chemotherapy and neoadjuvant chemotherapy, as well as dynamic treatment monitoring and prognosis evaluation. </s> |
<s>[INST] Provide title for trial id: NCT04239105 [/INST] Detection of Circulating Tumor Cells in Breast Cancer Patients Using a Novel Microfluidic and Raman Spectrum Device </s> |
<s>[INST] Provide the recruitment status for trial id: NCT04239105 [/INST] Unknown status </s> |
<s>[INST] Provide the medical condition for trial id: NCT04239105 [/INST] Breast Neoplasms, Circulating Tumor Cells </s> |
<s>Trial Id: Mobile Application Support for Women With Breast Cancer Undergoing Chemotherapy Recruitment Status: Recruiting Trail description: Mobile phones have become an essential tool for everyday life. The convenience and easy accessibility of the data and information received through mobile phones have made mobile applications as the latest trend to provide education for patients in medical centers. In Taiwan, breast cancer incidence has been the highest among all cancers and the fourth leading cause of cancer deaths in women. Women with breast cancer who are undergoing chemotherapy suffer from a number of symptoms throughout the chemotherapy treatment that detrimentally affects their quality of life. Thus, providing social support and nursing care aids for these vulnerable women is imperative to help them face their breast cancer challenges. This study will develop a Mobile device application providing medical care information and social support for breast cancer women during their chemotherapy treatment to help them receive individually tailored information related to chemotherapy and support from healthcare professionals and peers. This study will use a mixed-methods design to develop a Mobile device application based on breast cancer literature and the clinical experiences of breast cancer patients to fulfill the needs women may experience during the chemotherapy treatment. Women with breast cancer will be invited to help refine the Mobile device application's content based on their experiences and feedback about the mobile application. Upon completing the mobile application development, women with breast cancer patients will be recruited to participate in a randomized controlled trial to examine the effectiveness of the mobile application. The results of this study will provide a foundation to deliver a remote, personalized, and continuous health care model to improve the self-efficacy, social support, and quality of life of women with breast cancer, and ultimately enhancing the overall quality of care and patient satisfaction with the medical care participants receive. Inclusion Criteria: at least 20 years of age.
diagnosed with breast cancer for the first time.
treated with chemotherapy at the study sites.
able to access the internet with a mobile phone.
Fluent in spoken and written Chinese . Exclusion Criteria: patients with cognitive dysfunction.
diagnosed mental health problems.
having with other cancers. </s> |
<s>[INST] Provide inclusion criteria for trial id: NCT05072197 [/INST] at least 20 years of age.
diagnosed with breast cancer for the first time.
treated with chemotherapy at the study sites.
able to access the internet with a mobile phone.
Fluent in spoken and written Chinese . </s> |
<s>[INST] Provide exclusion criteria for trial id: NCT05072197 [/INST] patients with cognitive dysfunction.
diagnosed mental health problems.
having with other cancers. </s> |
<s>[INST] Provide description for trial id: NCT05072197 [/INST] Mobile phones have become an essential tool for everyday life. The convenience and easy accessibility of the data and information received through mobile phones have made mobile applications as the latest trend to provide education for patients in medical centers. In Taiwan, breast cancer incidence has been the highest among all cancers and the fourth leading cause of cancer deaths in women. Women with breast cancer who are undergoing chemotherapy suffer from a number of symptoms throughout the chemotherapy treatment that detrimentally affects their quality of life. Thus, providing social support and nursing care aids for these vulnerable women is imperative to help them face their breast cancer challenges. This study will develop a Mobile device application providing medical care information and social support for breast cancer women during their chemotherapy treatment to help them receive individually tailored information related to chemotherapy and support from healthcare professionals and peers. This study will use a mixed-methods design to develop a Mobile device application based on breast cancer literature and the clinical experiences of breast cancer patients to fulfill the needs women may experience during the chemotherapy treatment. Women with breast cancer will be invited to help refine the Mobile device application's content based on their experiences and feedback about the mobile application. Upon completing the mobile application development, women with breast cancer patients will be recruited to participate in a randomized controlled trial to examine the effectiveness of the mobile application. The results of this study will provide a foundation to deliver a remote, personalized, and continuous health care model to improve the self-efficacy, social support, and quality of life of women with breast cancer, and ultimately enhancing the overall quality of care and patient satisfaction with the medical care participants receive. </s> |
<s>[INST] Provide title for trial id: NCT05072197 [/INST] Mobile Application Support for Women With Breast Cancer Undergoing Chemotherapy </s> |
<s>[INST] Provide the recruitment status for trial id: NCT05072197 [/INST] Recruiting </s> |
<s>[INST] Provide the medical condition for trial id: NCT05072197 [/INST] Breast Neoplasms </s> |
<s>Trial Id: Breast Cancer Proteomics and Molecular Heterogeneity Recruitment Status: Recruiting Trail description: Primary objective:
The primary objective is to define the proteomic and molecular characteristics of primary and recurrent/ metastatic breast tumours with special focus on the expression of S100 protein and the estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2) genes
Secondary objective:
To expand our understanding of the complex molecular pathways dictating the progression of breast cancer and their response to different treatment regimes.
To relate proteomic findings to survival data
To identify potential serum markers of breast cancer progression Inclusion Criteria: None Exclusion Criteria: None </s> |
<s>[INST] Provide inclusion criteria for trial id: NCT01840293 [/INST] None </s> |
<s>[INST] Provide exclusion criteria for trial id: NCT01840293 [/INST] None </s> |
<s>[INST] Provide description for trial id: NCT01840293 [/INST] Primary objective:
The primary objective is to define the proteomic and molecular characteristics of primary and recurrent/ metastatic breast tumours with special focus on the expression of S100 protein and the estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2) genes
Secondary objective:
To expand our understanding of the complex molecular pathways dictating the progression of breast cancer and their response to different treatment regimes.
To relate proteomic findings to survival data
To identify potential serum markers of breast cancer progression </s> |
<s>[INST] Provide title for trial id: NCT01840293 [/INST] Breast Cancer Proteomics and Molecular Heterogeneity </s> |
<s>[INST] Provide the recruitment status for trial id: NCT01840293 [/INST] Recruiting </s> |
<s>[INST] Provide the medical condition for trial id: NCT01840293 [/INST] Primary Breast Cancer, Recurrent/Metastatic Breast Cancer </s> |
<s>Trial Id: Circulating Cancer Cells/Macrophage HYbrid Cells in Patients With Breast Cancer. Recruitment Status: Completed Trail description: Pilot, prospective, monocentric study aimed at evaluating the rate of patients with circulating cancer cell/macrophage hybrid cells in the peripheral blood.
The study will be conducted on a population of patients with breast cancer (regardless of stage of the disease and the immunohistochemical subtype).
For each included patient, blood samples will be taken and tumor specimens will be collected for the study.
At the end of the blood collection, the patient will have completed his participation in the study. Inclusion Criteria: Patient with breast cancer of any stage (stage I, II, III or IV) and any immunohistochemical subtype (triple-negative, HR+/HER2-negative or HER2-positive).
Patient not yet initiated on specific treatment for the stage of breast cancer at inclusion.
Available tumor sample (archived tumor block) : initial tumor or metastasis depending on the stage of the disease and availability.
Age ≥ 18 years old.
Patient affiliated to a Social Health Insurance in France.
Patient having signed informed consent prior to inclusion in the study and prior to any specific study procedure. Exclusion Criteria: Associated pathology(ies) that may prevent the proper conduct of the procedure under consideration.
Pregnant or breastfeeding woman.
Any psychological, family, geographical or sociological condition that prevents compliance with the medical follow-up and/or procedures of the study protocol.
Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship protection of justice).
Patient who has presented another solid tumor (except breast or cervix carcinoma in situ) within 5 years. </s> |
<s>[INST] Provide inclusion criteria for trial id: NCT04818125 [/INST] Patient with breast cancer of any stage (stage I, II, III or IV) and any immunohistochemical subtype (triple-negative, HR+/HER2-negative or HER2-positive).
Patient not yet initiated on specific treatment for the stage of breast cancer at inclusion.
Available tumor sample (archived tumor block) : initial tumor or metastasis depending on the stage of the disease and availability.
Age ≥ 18 years old.
Patient affiliated to a Social Health Insurance in France.
Patient having signed informed consent prior to inclusion in the study and prior to any specific study procedure. </s> |
<s>[INST] Provide exclusion criteria for trial id: NCT04818125 [/INST] Associated pathology(ies) that may prevent the proper conduct of the procedure under consideration.
Pregnant or breastfeeding woman.
Any psychological, family, geographical or sociological condition that prevents compliance with the medical follow-up and/or procedures of the study protocol.
Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship protection of justice).
Patient who has presented another solid tumor (except breast or cervix carcinoma in situ) within 5 years. </s> |
<s>[INST] Provide description for trial id: NCT04818125 [/INST] Pilot, prospective, monocentric study aimed at evaluating the rate of patients with circulating cancer cell/macrophage hybrid cells in the peripheral blood.
The study will be conducted on a population of patients with breast cancer (regardless of stage of the disease and the immunohistochemical subtype).
For each included patient, blood samples will be taken and tumor specimens will be collected for the study.
At the end of the blood collection, the patient will have completed his participation in the study. </s> |
<s>[INST] Provide title for trial id: NCT04818125 [/INST] Circulating Cancer Cells/Macrophage HYbrid Cells in Patients With Breast Cancer. </s> |
<s>[INST] Provide the recruitment status for trial id: NCT04818125 [/INST] Completed </s> |
<s>[INST] Provide the medical condition for trial id: NCT04818125 [/INST] Breast Cancer </s> |
<s>Trial Id: Blood Glycan Biomarkers in Women With Stage IV Breast Cancer Recruitment Status: Completed Trail description: RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur and identify biomarkers related to cancer.
PURPOSE: This research study is looking at blood glycan biomarkers in women with stage IV breast cancer. Inclusion Criteria: None Exclusion Criteria: None </s> |
<s>[INST] Provide inclusion criteria for trial id: NCT00897962 [/INST] None </s> |
<s>[INST] Provide exclusion criteria for trial id: NCT00897962 [/INST] None </s> |
<s>[INST] Provide description for trial id: NCT00897962 [/INST] RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur and identify biomarkers related to cancer.
PURPOSE: This research study is looking at blood glycan biomarkers in women with stage IV breast cancer. </s> |
<s>[INST] Provide title for trial id: NCT00897962 [/INST] Blood Glycan Biomarkers in Women With Stage IV Breast Cancer </s> |
<s>[INST] Provide the recruitment status for trial id: NCT00897962 [/INST] Completed </s> |
<s>[INST] Provide the medical condition for trial id: NCT00897962 [/INST] Breast Cancer </s> |
<s>Trial Id: Evaluation of Patients With Breast Cancer Using DCE-MRI, MRS, and Proteomics Recruitment Status: Completed Trail description: RATIONALE: Diagnostic procedures, such as dynamic contrast-enhanced magnetic resonance imaging(DCE-MRI), magnetic resonance spectroscopy (MRS), and tissue proteomics, may help doctors find and diagnose breast cancer and plan the best treatment.
PURPOSE: This clinical trial is studying MRI and MRS with or without tissue proteomics analysis to see how well they work in evaluating healthy women and women who are undergoing surgery for breast cancer. Inclusion Criteria: None Exclusion Criteria: None </s> |
<s>[INST] Provide inclusion criteria for trial id: NCT00656604 [/INST] None </s> |
<s>[INST] Provide exclusion criteria for trial id: NCT00656604 [/INST] None </s> |
<s>[INST] Provide description for trial id: NCT00656604 [/INST] RATIONALE: Diagnostic procedures, such as dynamic contrast-enhanced magnetic resonance imaging(DCE-MRI), magnetic resonance spectroscopy (MRS), and tissue proteomics, may help doctors find and diagnose breast cancer and plan the best treatment.
PURPOSE: This clinical trial is studying MRI and MRS with or without tissue proteomics analysis to see how well they work in evaluating healthy women and women who are undergoing surgery for breast cancer. </s> |
<s>[INST] Provide title for trial id: NCT00656604 [/INST] Evaluation of Patients With Breast Cancer Using DCE-MRI, MRS, and Proteomics </s> |
<s>[INST] Provide the recruitment status for trial id: NCT00656604 [/INST] Completed </s> |
<s>[INST] Provide the medical condition for trial id: NCT00656604 [/INST] Breast Cancer </s> |
<s>Trial Id: Awareness Scale Related To Physiotherapy After Breast Cancer: A Scale Development Study Recruitment Status: Recruiting Trail description: In this study, the aim is to develop a scale that assesses the awareness levels of particularly short and/or long-term effects, especially related to physiotherapy, in individuals diagnosed with high incidence and survival rates of breast cancer. Inclusion Criteria: Be over 18 years old
Be woman
Being diagnosed with breast cancer (individuals diagnosed with breast cancer who will start, start or have completed breast cancer treatment)
Being able to read and understand the Turkish language Exclusion Criteria: Having a cognitive impairment that interferes with answering questions
Be man </s> |
<s>[INST] Provide inclusion criteria for trial id: NCT05992441 [/INST] Be over 18 years old
Be woman
Being diagnosed with breast cancer (individuals diagnosed with breast cancer who will start, start or have completed breast cancer treatment)
Being able to read and understand the Turkish language </s> |
<s>[INST] Provide exclusion criteria for trial id: NCT05992441 [/INST] Having a cognitive impairment that interferes with answering questions
Be man </s> |
<s>[INST] Provide description for trial id: NCT05992441 [/INST] In this study, the aim is to develop a scale that assesses the awareness levels of particularly short and/or long-term effects, especially related to physiotherapy, in individuals diagnosed with high incidence and survival rates of breast cancer. </s> |
<s>[INST] Provide title for trial id: NCT05992441 [/INST] Awareness Scale Related To Physiotherapy After Breast Cancer: A Scale Development Study </s> |
<s>[INST] Provide the recruitment status for trial id: NCT05992441 [/INST] Recruiting </s> |
<s>[INST] Provide the medical condition for trial id: NCT05992441 [/INST] Breast Cancer </s> |
<s>Trial Id: Big Data and Text-mining Technologies Applied for Breast Cancer Medical Data Analysis Recruitment Status: Unknown status Trail description: Primary purpose :
To develop a method to automatically extract and structure the information included in numerous medical records from breast cancer patients.
Secondary purpose :
With this procedure we can analyze the content of ten thousand anonymized textual medical records.
This information should enable us to explore many subjects, such as:
The impact of certain therapeutic procedures
The characteristics of sub-groups of patients
Pregnancy associated breast cancers
Risk factors Inclusion Criteria: Majority (age > 18)
Malignant breast tumors
signed informed consent Exclusion Criteria: Benign breast pathology
Patients not initially treated at the Hôpitaux Universitaires de Strasbourg </s> |
<s>[INST] Provide inclusion criteria for trial id: NCT02810093 [/INST] Majority (age > 18)
Malignant breast tumors
signed informed consent </s> |
<s>[INST] Provide exclusion criteria for trial id: NCT02810093 [/INST] Benign breast pathology
Patients not initially treated at the Hôpitaux Universitaires de Strasbourg </s> |
<s>[INST] Provide description for trial id: NCT02810093 [/INST] Primary purpose :
To develop a method to automatically extract and structure the information included in numerous medical records from breast cancer patients.
Secondary purpose :
With this procedure we can analyze the content of ten thousand anonymized textual medical records.
This information should enable us to explore many subjects, such as:
The impact of certain therapeutic procedures
The characteristics of sub-groups of patients
Pregnancy associated breast cancers
Risk factors </s> |
<s>[INST] Provide title for trial id: NCT02810093 [/INST] Big Data and Text-mining Technologies Applied for Breast Cancer Medical Data Analysis </s> |
<s>[INST] Provide the recruitment status for trial id: NCT02810093 [/INST] Unknown status </s> |
<s>[INST] Provide the medical condition for trial id: NCT02810093 [/INST] Breast Cancer </s> |
<s>Trial Id: Prognostic and Predictive Factors for Small Breast Tumors Recruitment Status: Completed Trail description: Because of mammography screening increasingly more women are diagnosed with centimeter or subcentimeter node-negative breast cancer (i.e., T1abN0); these tumors account for approximately 19% of all newly diagnosed breast cancers in Sweden. Although the long term relapse-free survival rates among patients with such tumors is as high as ≥90%, some reports suggest that certain patient subgroups may have rates <75%. Firmly established prognostic and predictive factors for patients with T1abN0 tumors are, however, lacking. This is a nationwide, register-based cohort study investigating prognostic and predictive factors in women with centimeter or subcentimeter breast cancer. The study hypotheses are: 1) Established prognostic and/or predictive factors in overall breast cancer are prognostic and/or predictive factors also in centimeter or subcentimeter node-negative breast cancer; 2) The established relative reduction in risk of recurrence and death of adjuvant treatment for overall breast cancer are similar in centimeter or subcentimeter node-negative breast cancer. Inclusion Criteria: Female.
Operated for centimeter or subcentimeter breast cancer. Exclusion Criteria: Previous breast cancer.
Metastatic breast cancer at diagnosis. </s> |
<s>[INST] Provide inclusion criteria for trial id: NCT03390608 [/INST] Female.
Operated for centimeter or subcentimeter breast cancer. </s> |
<s>[INST] Provide exclusion criteria for trial id: NCT03390608 [/INST] Previous breast cancer.
Metastatic breast cancer at diagnosis. </s> |
<s>[INST] Provide description for trial id: NCT03390608 [/INST] Because of mammography screening increasingly more women are diagnosed with centimeter or subcentimeter node-negative breast cancer (i.e., T1abN0); these tumors account for approximately 19% of all newly diagnosed breast cancers in Sweden. Although the long term relapse-free survival rates among patients with such tumors is as high as ≥90%, some reports suggest that certain patient subgroups may have rates <75%. Firmly established prognostic and predictive factors for patients with T1abN0 tumors are, however, lacking. This is a nationwide, register-based cohort study investigating prognostic and predictive factors in women with centimeter or subcentimeter breast cancer. The study hypotheses are: 1) Established prognostic and/or predictive factors in overall breast cancer are prognostic and/or predictive factors also in centimeter or subcentimeter node-negative breast cancer; 2) The established relative reduction in risk of recurrence and death of adjuvant treatment for overall breast cancer are similar in centimeter or subcentimeter node-negative breast cancer. </s> |
<s>[INST] Provide title for trial id: NCT03390608 [/INST] Prognostic and Predictive Factors for Small Breast Tumors </s> |
<s>[INST] Provide the recruitment status for trial id: NCT03390608 [/INST] Completed </s> |
<s>[INST] Provide the medical condition for trial id: NCT03390608 [/INST] Breast Cancer </s> |
<s>Trial Id: Breast Cancer Molecular Analysis Protocol Recruitment Status: Completed Trail description: This is a molecular testing study for patients with metastatic breast cancer. The purpose of this study is to find defects in the DNA of the cancer that could potentially be treated with US Food and Drug Administration (FDA)approved or investigational drugs. For example, if your cancer has a mutation in the Epidermal Growth Factor Receptor (EGFR) gene (a mutation is a change int he DNA sequence of a gene) that makes this receptor "superactive" a drug that inhibits this receptor may also inhibit the growth of the cancer. If this genetic defect is not present in the cancer the same drug may not work. This EGFR gene mutation based patient selection for treatment has worked in lung cancer and we are testing its value in breast cancer. What drugs may be available against particular genetic abnormalities in the context of this clinical study will change over time. Inclusion Criteria: All patients with metastatic breast cancer who are considered for further systemic therapy are eligible regardless of number of prior therapies.
Patient must have a metastatic lesion that could be safely biopsied with or without image-guidance. The final arbiter to decide what lesion can be biopsied is the physician who will perform the biopsy.
There is no age limit for this study. However, this study will not include children because metastatic breast cancer does not occur in children.
Patients may participate in the biopsy study multiple times to repeat molecular assessment of the cancer after progression.
Patients who undergo routine clinical biopsy of metastatic breast cancer are also eligible to participate in this study. When the routine biopsies are obtained for diagnostic or other purposes, additional biopsies will be taken during the same biopsy session for molecular analysis. Exclusion Criteria: 1. Known medical contraindication for needle biopsy procedure such as bleeding disorder, low platelet count, inability to provide informed consent </s> |
<s>[INST] Provide inclusion criteria for trial id: NCT01855503 [/INST] All patients with metastatic breast cancer who are considered for further systemic therapy are eligible regardless of number of prior therapies.
Patient must have a metastatic lesion that could be safely biopsied with or without image-guidance. The final arbiter to decide what lesion can be biopsied is the physician who will perform the biopsy.
There is no age limit for this study. However, this study will not include children because metastatic breast cancer does not occur in children.
Patients may participate in the biopsy study multiple times to repeat molecular assessment of the cancer after progression.
Patients who undergo routine clinical biopsy of metastatic breast cancer are also eligible to participate in this study. When the routine biopsies are obtained for diagnostic or other purposes, additional biopsies will be taken during the same biopsy session for molecular analysis. </s> |
<s>[INST] Provide exclusion criteria for trial id: NCT01855503 [/INST] 1. Known medical contraindication for needle biopsy procedure such as bleeding disorder, low platelet count, inability to provide informed consent </s> |
<s>[INST] Provide description for trial id: NCT01855503 [/INST] This is a molecular testing study for patients with metastatic breast cancer. The purpose of this study is to find defects in the DNA of the cancer that could potentially be treated with US Food and Drug Administration (FDA)approved or investigational drugs. For example, if your cancer has a mutation in the Epidermal Growth Factor Receptor (EGFR) gene (a mutation is a change int he DNA sequence of a gene) that makes this receptor "superactive" a drug that inhibits this receptor may also inhibit the growth of the cancer. If this genetic defect is not present in the cancer the same drug may not work. This EGFR gene mutation based patient selection for treatment has worked in lung cancer and we are testing its value in breast cancer. What drugs may be available against particular genetic abnormalities in the context of this clinical study will change over time. </s> |
<s>[INST] Provide title for trial id: NCT01855503 [/INST] Breast Cancer Molecular Analysis Protocol </s> |
<s>[INST] Provide the recruitment status for trial id: NCT01855503 [/INST] Completed </s> |
<s>[INST] Provide the medical condition for trial id: NCT01855503 [/INST] Metastatic Breast Cancer </s> |
<s>Trial Id: Breast Cancer and Breast Self-examination Education Recruitment Status: Recruiting Trail description: According to a news published by the World Health Organization (WHO); More than 2.3 million cases of breast cancer occur each year, making it the most common cancer among adults. In 95% of all countries, breast cancer is the first or second cause of female cancer death. In 2020, 2.3 million women worldwide were diagnosed with breast cancer and 685,000 deaths occurred (WHO, 2023; https://www.who.int/news/item/03-02-2023-who-launches-new-roadmap- on-breast-cancer). In our country, breast cancer ranks first among the most common cancer types in women, and the number of breast cancer cases in women in 2020 was recorded as 74 638 (IARC, 2023). As a result of this situation, WHO (2023) published the Global Breast Cancer Initiative Framework to save 2.5 million lives from breast cancer by 2040. This published framework includes health promotion for early detection, timely diagnosis and comprehensive management of breast cancer.
One of the most effective ways to reduce breast cancer mortality and morbidity rate is early diagnosis. It is important to determine early diagnosis and signs and symptoms of cancer before they appear. Early diagnosis of breast cancer is possible with breast self-examination (BSE), clinical breast examination and mammography (Kayar, 2019). Breast self-examination is an important examination method in terms of detecting changes in breast tissue and preventing subsequent complications (Abo Al-Shiekh et al., 2021). It is also an easy-to-apply, cheap and non-invasive method. In our country, it is recommended that women regularly perform breast self-examination every month after the age of 20, women between the ages of 20 and 40 should have a clinical breast examination every two years, and women between the ages of 40 and 69 should have a clinical breast examination every year and have a mammogram every two years (Ministry of Health, 2019). .
There are studies showing that fear of breast cancer has a positive and negative impact on early diagnosis behaviors (Champion et al., 2004; Yavan et al., 2010). Champion et al. (2004) stated that women with moderate breast cancer fear had a high rate of early detection behavior, whereas low and high fear levels had a negative effect on behavior. In the study conducted by Yavan et al. (2010) on 188 women, 2% of the women. They found that 3 of them had regular BSE and 78.7% of them had never had a mammography. In addition, 85% of the women included in the study stated that they had a fear of breast cancer due to a family history of breast cancer, being diagnosed with breast cancer, and the presence of risk factors. Study results show that fear of breast cancer affects screening results. Therefore, our aim in the study is; To determine the effect of breast cancer and BSE training given to women on breast cancer fear and BSE skills. Inclusion Criteria: Able to read and write, Having no history of breast cancer, No communication barriers, Not pregnant or lactating, Those who are willing and agree to participate in the research. Exclusion Criteria: Having a mental illness, Those who wish to withdraw from any part of the research. </s> |
<s>[INST] Provide inclusion criteria for trial id: NCT06371508 [/INST] Able to read and write, Having no history of breast cancer, No communication barriers, Not pregnant or lactating, Those who are willing and agree to participate in the research. </s> |
<s>[INST] Provide exclusion criteria for trial id: NCT06371508 [/INST] Having a mental illness, Those who wish to withdraw from any part of the research. </s> |
<s>[INST] Provide description for trial id: NCT06371508 [/INST] According to a news published by the World Health Organization (WHO); More than 2.3 million cases of breast cancer occur each year, making it the most common cancer among adults. In 95% of all countries, breast cancer is the first or second cause of female cancer death. In 2020, 2.3 million women worldwide were diagnosed with breast cancer and 685,000 deaths occurred (WHO, 2023; https://www.who.int/news/item/03-02-2023-who-launches-new-roadmap- on-breast-cancer). In our country, breast cancer ranks first among the most common cancer types in women, and the number of breast cancer cases in women in 2020 was recorded as 74 638 (IARC, 2023). As a result of this situation, WHO (2023) published the Global Breast Cancer Initiative Framework to save 2.5 million lives from breast cancer by 2040. This published framework includes health promotion for early detection, timely diagnosis and comprehensive management of breast cancer.
One of the most effective ways to reduce breast cancer mortality and morbidity rate is early diagnosis. It is important to determine early diagnosis and signs and symptoms of cancer before they appear. Early diagnosis of breast cancer is possible with breast self-examination (BSE), clinical breast examination and mammography (Kayar, 2019). Breast self-examination is an important examination method in terms of detecting changes in breast tissue and preventing subsequent complications (Abo Al-Shiekh et al., 2021). It is also an easy-to-apply, cheap and non-invasive method. In our country, it is recommended that women regularly perform breast self-examination every month after the age of 20, women between the ages of 20 and 40 should have a clinical breast examination every two years, and women between the ages of 40 and 69 should have a clinical breast examination every year and have a mammogram every two years (Ministry of Health, 2019). .
There are studies showing that fear of breast cancer has a positive and negative impact on early diagnosis behaviors (Champion et al., 2004; Yavan et al., 2010). Champion et al. (2004) stated that women with moderate breast cancer fear had a high rate of early detection behavior, whereas low and high fear levels had a negative effect on behavior. In the study conducted by Yavan et al. (2010) on 188 women, 2% of the women. They found that 3 of them had regular BSE and 78.7% of them had never had a mammography. In addition, 85% of the women included in the study stated that they had a fear of breast cancer due to a family history of breast cancer, being diagnosed with breast cancer, and the presence of risk factors. Study results show that fear of breast cancer affects screening results. Therefore, our aim in the study is; To determine the effect of breast cancer and BSE training given to women on breast cancer fear and BSE skills. </s> |
<s>[INST] Provide title for trial id: NCT06371508 [/INST] Breast Cancer and Breast Self-examination Education </s> |
<s>[INST] Provide the recruitment status for trial id: NCT06371508 [/INST] Recruiting </s> |
<s>[INST] Provide the medical condition for trial id: NCT06371508 [/INST] Breast Cancer, Breast Self-Examination </s> |
<s>Trial Id: Genomic Grade Index (GGI): Feasibility in Routine Practice and Impact on Treatment Decisions in Early Breast Cancer Recruitment Status: Completed Trail description: In this prospective study the investigators sought to evaluate the feasibility of using the genomic signature - Genomic Grade Index (GGI) - in routine clinical practice and its impact on treatment recommendations. Inclusion Criteria: Histologically confirmed invasive breast cancer meeting the following criteria:
T1, T2, or operable T3 disease
Zero to three positive lymph nodes and no distant metastases
Operable disease - Must have undergone breast-conserving surgery or mastectomy with either a sentinel node procedure or full axillary clearance Exclusion Criteria: No other invasive cancer within the past 5 years except for adequately treated carcinoma in situ of the cervix or non melanoma skin cancer
No psychological, familial, sociological, or geographical condition that would preclude entering into a clinical study </s> |
<s>[INST] Provide inclusion criteria for trial id: NCT01916837 [/INST] Histologically confirmed invasive breast cancer meeting the following criteria:
T1, T2, or operable T3 disease
Zero to three positive lymph nodes and no distant metastases
Operable disease - Must have undergone breast-conserving surgery or mastectomy with either a sentinel node procedure or full axillary clearance </s> |
<s>[INST] Provide exclusion criteria for trial id: NCT01916837 [/INST] No other invasive cancer within the past 5 years except for adequately treated carcinoma in situ of the cervix or non melanoma skin cancer
No psychological, familial, sociological, or geographical condition that would preclude entering into a clinical study </s> |
<s>[INST] Provide description for trial id: NCT01916837 [/INST] In this prospective study the investigators sought to evaluate the feasibility of using the genomic signature - Genomic Grade Index (GGI) - in routine clinical practice and its impact on treatment recommendations. </s> |
<s>[INST] Provide title for trial id: NCT01916837 [/INST] Genomic Grade Index (GGI): Feasibility in Routine Practice and Impact on Treatment Decisions in Early Breast Cancer </s> |
<s>[INST] Provide the recruitment status for trial id: NCT01916837 [/INST] Completed </s> |
<s>[INST] Provide the medical condition for trial id: NCT01916837 [/INST] Invasive Breast Cancer </s> |
<s>Trial Id: Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software Recruitment Status: Completed Trail description: Patients with early breast cancer were randomized at the final visit of adjuvant radiotherapy to surveillance by phone calls or by mobile Noona software. After six months the groups were crossed over to the other arm. At 12 months the patients were asked their preference which was the primary end-point. At baseline, 6 months and 12 months the patients answered the other questionnaires. Inclusion Criteria: Adult patients with early breast cancer after primary treatment including also radiotherapy (the patients were randomized at the final visit of radiotherapy) Exclusion Criteria: not able to use a computer
another malignancy </s> |
<s>[INST] Provide inclusion criteria for trial id: NCT04980989 [/INST] Adult patients with early breast cancer after primary treatment including also radiotherapy (the patients were randomized at the final visit of radiotherapy) </s> |
<s>[INST] Provide exclusion criteria for trial id: NCT04980989 [/INST] not able to use a computer
another malignancy </s> |
<s>[INST] Provide description for trial id: NCT04980989 [/INST] Patients with early breast cancer were randomized at the final visit of adjuvant radiotherapy to surveillance by phone calls or by mobile Noona software. After six months the groups were crossed over to the other arm. At 12 months the patients were asked their preference which was the primary end-point. At baseline, 6 months and 12 months the patients answered the other questionnaires. </s> |
<s>[INST] Provide title for trial id: NCT04980989 [/INST] Follow-up of Early Breast Cancer (BC) Patients by Telephone or Mobile Software </s> |
<s>[INST] Provide the recruitment status for trial id: NCT04980989 [/INST] Completed </s> |
<s>[INST] Provide the medical condition for trial id: NCT04980989 [/INST] Breast Cancer, Early-Onset </s> |
<s>Trial Id: The Development of a Personalized Decision Aid: Perspectives of Patients and Health Care Professionals on Shared Decision Making and Informational Needs on Radiotherapy for Breast Cancer Recruitment Status: Completed Trail description: Background: The Dutch guideline on breast cancer treatment shows several grey areas, where no clear recommendation is given on the radiotherapy options, but where the advice is to discuss the treatment of choice with the patient. Currently, patients are exposed to different information given by the professionals' personal styles of informing patients. The challenge for all oncological professionals is to give clear, structured, and neutral information on the pros and cons of the treatment option(s) in the context of the natural course of the disease to the patient; to elicit patients' needs and preferences. How and which information should be shared in a decision aid is up for investigation, as well as how this should best be implemented.
Research goals: Qualitative assessment of patients' and health care professionals' informational needs and perspectives on breast cancer radiotherapy and shard decision making.
Methods: Semi-structured interviews will be held with both breast cancer patients and health care professionals. To reach as heterogeneous groups as possible patients of different ages, with different education levels and who underwent different treatments or chose not to get radiotherapy at all will be selected . Data will be collected til saturation is reached. Interviews will be transcribed verbatim and analysed using thematic analysis.
Results: Results of the qualitative study are expected at the beginning of 2017.
Hypothesis: Investigating the patients' and health care professionals' perspectives on shared decision making and informational needs on radiotherapeutic options will help the development of a personalized decision aid eligible for broad implementation. Inclusion Criteria: 2-3 months after facing decision or > 1 year after decision
able to speak and understand Dutch
Written informed consent Exclusion Criteria: recurrence of breast cancer prior to interview </s> |
<s>[INST] Provide inclusion criteria for trial id: NCT02934126 [/INST] 2-3 months after facing decision or > 1 year after decision
able to speak and understand Dutch
Written informed consent </s> |
<s>[INST] Provide exclusion criteria for trial id: NCT02934126 [/INST] recurrence of breast cancer prior to interview </s> |
<s>[INST] Provide description for trial id: NCT02934126 [/INST] Background: The Dutch guideline on breast cancer treatment shows several grey areas, where no clear recommendation is given on the radiotherapy options, but where the advice is to discuss the treatment of choice with the patient. Currently, patients are exposed to different information given by the professionals' personal styles of informing patients. The challenge for all oncological professionals is to give clear, structured, and neutral information on the pros and cons of the treatment option(s) in the context of the natural course of the disease to the patient; to elicit patients' needs and preferences. How and which information should be shared in a decision aid is up for investigation, as well as how this should best be implemented.
Research goals: Qualitative assessment of patients' and health care professionals' informational needs and perspectives on breast cancer radiotherapy and shard decision making.
Methods: Semi-structured interviews will be held with both breast cancer patients and health care professionals. To reach as heterogeneous groups as possible patients of different ages, with different education levels and who underwent different treatments or chose not to get radiotherapy at all will be selected . Data will be collected til saturation is reached. Interviews will be transcribed verbatim and analysed using thematic analysis.
Results: Results of the qualitative study are expected at the beginning of 2017.
Hypothesis: Investigating the patients' and health care professionals' perspectives on shared decision making and informational needs on radiotherapeutic options will help the development of a personalized decision aid eligible for broad implementation. </s> |
<s>[INST] Provide title for trial id: NCT02934126 [/INST] The Development of a Personalized Decision Aid: Perspectives of Patients and Health Care Professionals on Shared Decision Making and Informational Needs on Radiotherapy for Breast Cancer </s> |
<s>[INST] Provide the recruitment status for trial id: NCT02934126 [/INST] Completed </s> |
<s>[INST] Provide the medical condition for trial id: NCT02934126 [/INST] Breast Cancer </s> |
<s>Trial Id: Individualized Risk-Based Education in Promoting Breast Cancer Screening in Healthy Women Recruitment Status: Completed Trail description: RATIONALE: Education, based on a patient's risk factors, may help promote breast cancer screening in healthy women.
PURPOSE: This randomized clinical trial is studying individualized risk-based education to see how well it promotes breast cancer screening in healthy women compared to standard education. Inclusion Criteria: None Exclusion Criteria: None </s> |